NCT01260779No Longer Available不适用
Open Label Expanded Access for Investigational Use of PV-10 in Patients Who Are Not Eligible for an Existing PV-10 Clinical Trial, for Whom There is no Alternative Therapy, and Whom May Benefit From PV-10 Administration
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- No Longer Available
- 试验地点
- 6
研究概览
简要总结
This compassionate use protocol provides expanded access for investigational use of PV-10 in cancer patients who are not eligible for an existing PV-10 clinical trial, for whom there is no comparable or satisfactory approved alternative therapy and whom, in the opinion of the investigator, may benefit from PV-10 administration.
研究设计
- 研究类型
- Expanded Access
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age 18 years or older, male or female.
- •Histologically or cytologically confirmed cancer where there is no comparable or satisfactory approved alternative therapy specific to cutaneous or subcutaneous tumors.
- •Performance Status: ECOG 0-
- •Life Expectancy: At least 6 months.
- •Blood Chemistry:
- •Creatinine ≤ 3 times the upper limit of normal (ULN).
- •Total bilirubin ≤ 3 times the upper limit of normal (ULN).
- •AST/ALT/ALP ≤ 5 times the upper limit of normal (ULN).
- •Thyroid Function
- •Total T3 or free T3 (serum triiodothyronine), total T4 or free T4 (serum thyroxine) and THS (serum thyrotropin) ≤ grade 2 abnormality.
- •Renal Function
- •Subjects must have adequate renal function in the opinion of the Investigator with no clinically significant renal impairment or uncontrolled renal disease.
排除标准
- •Cancer patients who are eligible for an existing PV-10 clinical trial.
- •Certain photosensitizing agents within 5 half-lives prior to PV-10 administration.
- •Concurrent or Intercurrent Illness:
- •Subjects with uncontrolled diabetes or extremity complications due to diabetes.
- •Subjects with severe peripheral vascular disease.
- •Subjects with significant concurrent or intercurrent illness, psychiatric disorders, or alcohol or chemical dependence that would, in the opinion of the Investigator, compromise their safety or compliance or interfere with interpretation of study results.
- •Subjects with uncontrolled thyroid disease, goiter, partial thyroidectomy, radioiodine- or surgically-treated Graves' hyperthyroidism or cystic fibrosis.
- •Subjects with clinically significant acute or unstable cardiovascular, (stroke), renal, gastrointestinal, pulmonary, immunological (with the exception of the presence of hepatitis B virus (HBV), viral hepatitis, or cirrhosis), endocrine, or central nervous system disorders.
- •Female subjects who are pregnant or lactating.
- •Female subjects who have positive serum ßHCG pregnancy test taken within 7 days of PV-10 administration.
- •Fertile subjects who are not using effective contraception.
- •Investigational Agents:
- •Subjects who have received investigational agents within 4 weeks (or 5 half-lives) of study administration.
研究者
研究点 (6)
Loading locations...
相似试验
No Longer Available
不适用
Expanded Access for PSV Personalized Oncolytic VirusesCancerNCT03529539EpicentRx, Inc.
Available
不适用
Sponsor Initiated Expanded Access Protocol, Intermediate-Size Patient PopulationLigneous ConjunctivitisNCT04586062Kedrion S.p.A.
Unknown
不适用
An Open Label, Expanded Access Protocol With SAGE-547 for Super-Refractory Status EpilepticusSuper-Refractory Status EpilepticusNCT02433314Supernus Pharmaceuticals, Inc.
终止
3 期
Open Label Extension Study of STX209 (Arbaclofen) in Autism Spectrum DisordersAutism Spectrum DisordersNCT01706523Seaside Therapeutics, Inc.165
No Longer Available
不适用
Expanded Access (Compassionate Use) Treatment Protocol RindopepimutRecurrent GBMNCT03068650Celldex Therapeutics